Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines
The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Protoporphyrin IX (PpIX) is the photosensitizer in 5-aminolaevulinic acid (ALA)-based photodynamic therapy (PDT). Its further bioconversion to heme requires iron and can be suppressed by iron chelators such as desferrioxamine (DFO). To investigate the effectiveness of DFO in enhancing PpIX-based PDT in skin tissue, we selected fibroblasts, HaCat cells and Hep-2 cells as targets co-cultured with ALA, that have different biological characteristics for PpIX conversion. Evaluated interventions included: (1) blank control (no ALA, no DFO); (2) DFO alone; (3) ALA alone; and (4) DFO in combination with ALA. Before photodynamic irradiation, cellular PpIX level and fluorescence were measured. After irradiation, cell death ratio was calculated and morphological changes in the cells were observed. The results showed that the content and photodynamic effects of cellular PpIX presented in the order Hep-2 cells > HaCat cells > fibroblasts, either co-cultured with ALA alone or with ALA plus DFO. DFO was found to have increasing effects on both PpIX level and cell death ratio in the same order. It was found that DFO had different potentials for augmenting ALA-PDT in these cutaneous cell lines. The cells proliferating more rapidly might be more susceptible to enhancement of DFO.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DFO has been demonstrated to enhance PpIX fluorescence and/or PDT effects in various studies with different cell lines including skin, bladder, and glioblastoma tumor cells [86,87,88,89,90].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [88]
In the citing paper
“Chelator-induced PpIX enhancement is more pronounced at low doses of ALA than at the high doses of ALA that are typically used.”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [88]
In the citing paper
“It turns out that the effects of iron chelators on ALA-PpIX fluorescence are highly dependent on the cell line and ALA dose [85,88,92,105].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [88]
Citations
Cites
Guidelines for topical photodynamic therapy: update
Morton, C. A., McKenna, K. E., Rhodes, L. E., & on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08882.x · Cited by 471
ALA and its clinical impact, from bench to bedside
Krammer, B., & Plaetzer, K. (2008) · Photochemical & Photobiological Sciences · doi:10.1039/b712847a · Cited by 251
Chen, S., Cheng, A.-C., Wang, M.-S., & Peng, X. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2174 · Cited by 167
Aminolevulinic acid: From its unique biological function to its star role in photodynamic therapy
Fukuda, H., Casas, A., & Batlle, A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.04.018 · Cited by 127
de Haas, E. R. M., Kruijt, B., Sterenborg, H. J. C. M., Martino Neumann, H. A., & Robinson, D. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700460 · Cited by 118
Pretreatment to Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy
Gerritsen, M. J. P., Smits, T., Kleinpenning, M. M., van de Kerkhof, P. C. M., & van Erp, P. E. J. (2009) · Dermatology · doi:10.1159/000183753 · Cited by 113
Cellular Uptake and Release of Two Contrasting Iron Chelators
Cable, H., & Lloyd, J. B. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772231 · Cited by 102
Akilov, O. E., Kosaka, S., O’Riordan, K., & Hasan, T. G. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00578.x · Cited by 99
Oleic Acid as Optimizer of the Skin Delivery of 5-Aminolevulinic Acid in Photodynamic Therapy
Pierre, M. B. R., Ricci‐Júnior, E., Tedesco, A. C., & Bentley, M. V. L. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-9261-x · Cited by 83
Šmucler, R., & Vlk, M. (2008) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20606 · Cited by 81
Effect of 5‐aminolevulinic acid‐mediated photodynamic therapy on MCF‐7 and MCF‐7/ADR cells
Tsai, T., Hong, R., Tsai, J., Lou, P., Ling, I., & Chen, C. (2004) · Lasers in Surgery and Medicine · doi:10.1002/lsm.10246 · Cited by 72
Effect of iron chelators on proliferation and iron uptake in hepatoma cells
Kicic, A., Chua, A. C. G., & Baker, E. (2001) · Cancer · doi:10.1002/1097-0142(20011215)92:12<3093::aid-cncr10107>3.0.co;2-b · Cited by 70
Photodynamic Therapy for Nonmelanoma Skin Cancer
Keller, G. S., Razum, N. J., & Doiron, D. R. (1989) · Facial Plastic Surgery · doi:10.1055/s-2008-1064728 · Cited by 66
Photodynamic Therapy for Non-Melanoma Skin Cancer
Fien, S., & Oseroff, A. R. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0046 · Cited by 58
Evaluation of the penetration of 5‐aminolevulinic acid through basal cell carcinoma: a pilot study
Ahmadi, S., McCarron, P. A., Donnelly, R. F., Woolfson, A. D., & McKenna, K. (2004) · Experimental Dermatology · doi:10.1111/j.0906-6705.2004.00181.x · Cited by 55
Tsai, J., Wu, C., Chien, H., & Chen, C. (2005) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20179 · Cited by 54
Ca, M., Ke, M., & Rhodes, L. E. (2008) · British Journal of Dermatology · Cited by 53
van den Akker, J. T. H. M., Boot, K., Vernon, D. I., Brown, S. B., Groenendijk, L., van Rhoon, G. C., & Sterenborg, H. J. C. M. (2004) · Photochemical & Photobiological Sciences · doi:10.1039/b309284d · Cited by 53
Kuželová, K., Grebeňová, D., Pluskalová, M., Marinov, I., & Hrkal, Z. (2004) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2003.07.007 · Cited by 50
Pye, A., & Curnow, A. (2007) · Photochemistry and Photobiology · doi:10.1562/2006-05-30-ra-906 · Cited by 45
Boddé, H. E., Roemelé, P. E. H., & Star, W. M. (2002) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2002)0750418qotdaa2.0.co2 · Cited by 43
The influence of photodynamic therapy on apoptosis in human melanoma cell line.
Saczko, J., Kulbacka, J., Chwiłkowska, A., Drąg‐Zalesińska, M., Wysocka, T., Ługowski, M., & Banaś, T. (2005) · PubMed · doi:10.5603/4608 · Cited by 38
Jin, H., Terai, S., & Sakaida, I. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2020-5 · Cited by 37
Excited state properties and in vitro phototoxicity studies of three phenothiazine derivatives
F., E., L., L., G., A., et al. (2002) · Pure Amsterdam UMC · doi:10.1562/0031-8655(2002)075 · Cited by 33
Lee, J. B., Choi, J. Y., Chun, J. S., Yun, S. J., Lee, S. C., Oh, J., & Park, H. R. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08611.x · Cited by 32
Gilmore, B., McCarron, P. A., Morrow, D. I. J., Murphy, D. J., Woolfson, A. D., & Donnelly, R. F. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.03.002 · Cited by 28
Pye, A., & Curnow, A. (2007) · Journal of Environmental Pathology, Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v26.i2.40 · Cited by 23
Lü, S., Chen, J.-Y., Zhang, Y., Ma, J., Wang, P.-N., & Peng, Q. (2008) · Journal of Biomedical Optics · doi:10.1117/1.2907316 · Cited by 21
Ayala, F., Grimaldi, E., Perfetto, B., Donnarumma, M., Filippis, A. D., Donnarumma, G., & Tufano, M. A. (2008) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2008.00367.x · Cited by 21
Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy.
Liu, H., Xu, S., & Zhang, C. (2004) · PubMed · Cited by 21
Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy.
刘辉峰, 徐世正, & 张春荣 (2004) · PubMed · Cited by 21
Topical applications of iron chelators in photosensitization
Juzeniene, A., Juzenas, P., Iani, V., & Moan, J. E. (2007) · Photochemical & Photobiological Sciences · doi:10.1039/b703861e · Cited by 20
Ziolkowski, P. P., Osiecka, B. J., Siewiński, M., Bronowicz, A., Ziółkowska, J., & Gerber, H. (2006) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v25.i1-2.250 · Cited by 19
Differential regulation on human skin fibroblast by α1 adrenergic receptor subtypes
Sterin‐Borda, L., Furlán, C., Orman, B. E., & Borda, E. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.041 · Cited by 17
5-Aminolevulinic Acid-Mediated Photodynamic Therapy on Hep-2 and MCF-7c3 Cells
Alvarez, M. G., Lacelli, M. S., Rivarola, V. A., Batlle, A. M. D. C., & Fukuda, H. (2007) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v26.i2.20 · Cited by 13
Konaç, E., Ekmekçi, A., Yurtçu, E., & Ergün, M. A. (2005) · PubMed · Cited by 13
金, 海. (2008) · Medical Entomology and Zoology · Cited by 13
Paradoxical Effects of Iron Chelation on Growth of Vascular Endothelial Cells
Hodges, Y. K., Reese, S. M., Pahl, P. M. B., & Horwitz, L. D. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000159659.78675.4a · Cited by 9
Cited by
Current states and future views in photodynamic therapy
Yano, S., Hirohara, S., Obata, M., Hagiya, Y., Ogura, S.-I., Ikeda, A., Kataoka, H., Tanaka, M., & Joh, T. (2011) · Journal of Photochemistry and Photobiology C: Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2011.06.001 · Cited by 540
Yang, X., Palasuberniam, P., Kraus, D., & Chen, B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025865 · Cited by 158
“A more potent and selective iron chelator deferoxamine (DFO) [65] was later found to increase ALA-PpIX accumulation and sensitivity to ALA-PDT in a variety of tumor cells and tissues [66–71].”
BackgroundHagiya, Y., Endo, Y., Yonemura, Y., Takahashi, K., Ishizuka, M., Abe, F., Tanaka, T., Okura, I., Nakajima, M., Ishikawa, T., et al. (2012) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2011.12.004 · Cited by 129
Zhao, S., Chen, X., Wang, L.-G., Yang, G., Han, D., Teng, L., Yang, M., Wang, D.-Y., Shi, C., Liu, Y.-H., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2201-6 · Cited by 111
Wang, W., Tabu, K., Hagiya, Y., Sugiyama, Y., Kokubu, Y., Murota, Y., Ogura, S., & Taga, T. (2017) · Scientific Reports · doi:10.1038/srep42070 · Cited by 70
Metadata
- Authors
- Yang, J., Xia, Y., Liu, X., Jiang, S., & Xiong, L.
- Affiliations
- Yangtze University (CN)
- Renmin Hospital of Wuhan University (CN)
- Corresponding author
- Xia, Yumin
- Venue
- Lasers in Medical Science
- Published
- 2009-08-25
- Volume
- 25
- Issue
- 2
- Pages
- 251-257
- ISSN
- 0268-8921 (ISSN-L)
- 1435-604X
- OpenAlex
- W2034013141
- Cited by
- 28
- References
- 36
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 2 · 2013: 1 · 2012: 2
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lasers in Medical Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wuhan University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- deferoxamine, 5-aminolevulinic acid, photodynamic therapy, protoporphyrin IX, iron chelators, heme biosynthesis, HaCaT keratinocytes, HEp-2 cells, fibroblasts, cell death, skin cancer
- MeSH terms
- Aminolevulinic Acid, Cell Line, Deferoxamine, Drug Synergism, Fibroblasts, Humans, Iron Chelating Agents, Photochemotherapy, Protoporphyrins, Skin Diseases, Cell Death, Photosensitizing Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.